In the United States, the annual number of total hip arthroplasties (THAs) among patients over the age of 45 years doubled over 11 years to approximately 310 800 in 2010.
| INTRODUC TI ON
In the United States, the annual number of total hip arthroplasties (THAs) among patients over the age of 45 years doubled over 11 years to approximately 310 800 in 2010. 1 During this same period, the rate of total knee arthroplasties (TKAs) increased 86% to 45.3 per 10 000 for men and 99% to 65.5 per 10 000 for women. 
States is projected to increase by nearly 200% and the number of
TKAs is projected to increase by over 600%. 3 Lower extremity joint replacement (LEJR) is one of the most common procedures performed among Medicare beneficiaries. 4 Significant variation in spending for surgical procedures exists across US hospitals. 5 Variability in cost is explained by the post acute episode of care, 6, 7 type of joint implant, 8 geographic region, 9 and type of medical center. 9 Age, 9-13 disease severity, 6 ,10,14-16 socioeconomic status and social determinants of health, 9, [17] [18] [19] and medical comorbidities are associated with increased LEJR costs. 9, 11, [20] [21] [22] [23] [24] [25] In 
| ME THODS

| Study population
This study performed secondary data analyses of Medicare FFS data for patients discharged from an acute care hospital for a CJR-qualifying LEJR procedure in 2013 ( Figure 1 
| Patient measures
Medicare FFS data contain some patient-level information that may be informative in correctly assigning patients to expected cost groups, which can be helpful in risk adjustment and payment stratifi- the impact of body fat as a proxy for complexity of patient health status and necessary recovery care, laterality of the procedure (right vs.
left joint), and marital status as a proxy for social support.
To further our understanding of how patient-reported measures could also play a role in assignment of patients to episode cost groups for CJR-qualifying LEJR episodes, we chose to also analyze the data resources available within our own Mayo Clinic health care system. Mayo Clinic Rochester is a large multidisciplinary practice in the Midwest. The measures included questions routinely collected for clinical care within our system, which was not a standard practice among other HVHC member organizations.
| Primary outcome: 90-day episode cost
The primary outcome of interest was the total 90-day episode cost Index was used to determine optimal cut points for evaluation. 34 This index optimizes the cut point by maximizing the combined sensitivity and specificity measures: Youden Index = sensitivity + specificity − 1. This index was used in lieu of fixed sensitivity due to the nature of the binary predictors in our models limiting the ability to choose a fixed sensitivity.
| Statistical analysis
Additionally, we estimated the same multivariate models against the continuous total 90-day episode cost outcome for comparison.
Because health care costs are not normally distributed, we estimated a generalized linear model with a gamma distribution and log link transformation. Regression estimates were converted back to costs for interpretation. To examine the incremental value of the models, we calculated R 2 estimates for generalized linear models using methods developed by Zhang. 35 We report both estimated R 2 and the penalized R 2 to adjust for additional parameters in the full model. Results for these supplemental analyses can be found within Supporting information. All analysis was carried out using SAS 9.4 (Cary, NC). reported that they could climb two flights of stairs with difficulty, and 24.0% reported that they could climb two flights of stairs with no difficulty.
| RE SULTS
| Patient factors across cost categories
When patient-level factors were modeled univariately against the 80%/20% dichotomized 90-day episode costs, factors associated with high-cost episodes (top 20%) included our youngest and oldest age groups (< 65 years; ≥80 years) (P < 0.0001 for CMS, HVHC, Mayo Clinic), dual eligibility status (CMS P < 0.0001; HVHC P < 0.0001; Mayo Clinic P = 0.0015), having a hip or "other" procedure (ie, complications of orthopedic device, fractures, or degeneration of the lower extremity) vs a knee or ankle procedure (CMS P < 0.0001; HVHC P = 0.0073, Mayo Clinic P = 0.0382), and residence in an urban (CMS P < 0.0001; HVHC P = NS; Mayo Clinic P = NS) or rural setting (CMS P = NS; HVHC P = NS; Mayo Clinic P = 0.0009).
Within our HVHC and Mayo Clinic subpopulations, our ability to look at different patient factors varied due to data availability. The inability to climb two flights of stairs was associated with high-cost episodes (Mayo Clinic, P < 0.0001). Unmarried status was associated with higher cost compared to married or having a life partner (HVHC:
19.6% vs 9.3%, P < 0.0001; Mayo Clinic: 16.7% vs 9.3%, P = 0.0013).
BMI (<30 and ≥30) was not associated with cost (HVHC: P = 0.495;
Mayo Clinic: P = 0.2204).
The five most prevalent individual CMS-HCC groups identified were congestive heart failure, vascular disease, specified heart arrhythmias, dementia without complication, and chronic 
| 90-day episode costs
Median total episode costs increased with the increased severity (MS-DRG) and hip fracture status ( 
| Models identifying high-cost episodes
The base model, which included hip fracture status and pro- Similar findings were observed in the continuous outcome models with increased explanatory ability (ie, higher R 2 and penalized R 2 ) as measured of interest were added. Additional detail regarding these results can be found in the online technical appendices.
| D ISCUSS I ON
We observed that younger (<65 years) and older (≥80 years) age, dual eligibility status, having a nonknee or ankle procedure, and residence in an urban setting for the entire CMS cohort, and residence in a rural setting for the Mayo Clinic cohort were associated with higher episode costs. We observed that adding CMS-HCC categories improved our ability to identify patients who were in the top 20% of episode costs. We also observed that variables derived from administrative data and clinical sources, particularly functional status, improved our ability to identify patients within different cost groups.
Our findings add to the extant literature by demonstrating that CMS-HCC increases the ability to identify patients who are higher cost in a population of patients undergoing LEJR. Concerns have existed about the accuracy of the CMS-HCC for predicting patient care costs. 36-38 CMS had not included CMS-HCC risk adjustment in the CJR rule because it had not been validated in a group of patients undergoing LEJR. Our data provide support to the inclusion of CMS-HCC risk adjustment in future bundled payment models for patients undergoing LEJR.
Our data suggest that the inclusion of clinical factors such as functional status may improve the ability to predict patients with greater episode costs. C-statistics greater than 0.70 are considered good and clinically relevant, and C-statistics greater than 0.80 are considered strong. 39 The highest C-statistic we observed was for the base model in addition to CMS-HCC and functional status (defined as being ability to climb two flights of stairs) in the Mayo Clinic 
TA B L E 1 (Continued)
PHILPOT eT aL. Previous investigators have suggested that the financially dominant strategy for most hospitals under CJR would be to accept
Medicare penalties and not make any investments in CJR or care management. 41 This result is partially driven by the significant upfront investments in care redesign and the inability to recover these costs for low-volume hospitals. However, for commoditized procedures like LEJR, significant cost reductions can be obtained through interventions which do not require potentially expensive care redesign efforts such as reducing implant costs or avoiding higher cost postacute care. 42 Our findings provide information that could enhance the tailoring of care management pathways to reduce costs for patients more likely to incur greater costs. An unintended consequence is that our findings could be used to offer procedures to lower-risk, lower-cost patients. Indeed, a previous study has observed a statistically significant decrease in the average age and comorbidity of patients undergoing LEJR among academic centers during the risk-bearing period of bundled payment for LEJR. 43 The inclusion of HCC risk scores in LEJR reconciliation payments would lead to annual reductions in payments by as much as $146 360 for hospitals caring for the least medically complex patients and increases as large as $114 184 for hospitals with the most medically complex patients. 28 These financial shifts in a cost-neutral approach to reimbursement for CMS programs would serve to decrease the likelihood of adverse patient selection for higher cost patients.
Several limitations to our analysis exist. First, data availability varied across the three study cohorts used in our analysis due to the nature of data collection from Medicare claims, across differing HVHC member organizations, and at Mayo Clinic. This limited our power for detecting differences between groups and limited our ability to capture the potential effects of certain patient factors. TA B L E 3 Incremental modeling of 90-day episode cost for lower extremity joint replacement (LEJR) for CMS, HVHC, and Mayo Clinic, Rochester, Minnesota populations (2013). All estimates were calculated utilizing the Youden Index for selecting optimal cut points for evaluation PHILPOT eT aL.
of claims population, we had a very large sample size which allowed for potentially irrelevant differences to be detected. 
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